Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongliang Shi

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
American Journal of Hematology|January 6, 2015
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA studyMaría Victoria Mateos, Paul G Richardson, Meletios A Dimopoulos, et al.
ACS Applied Materials & Interfaces|May 25, 2019
Stability and Repeatability of a Karst-like Hierarchical Porous Silicon Oxide-Based MemristorQin Gao, Anping Huang, Qi Hu, et al.
ACS Omega|August 29, 2019
Broadband Emission in Hybrid Organic-Inorganic Halides of Group 12 MetalsRachel Roccanova, Matthew Houck, Aymen Yangui, et al.
Blood|March 17, 2012
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myelomaShaji Kumar, Ian Flinn, Paul G Richardson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2011
Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL studyNathan Fowler, Brad S Kahl, Peter Lee, et al.
European Urology|April 11, 2020
The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 TrialDavid P Dearnaley, Daniel R Saltzstein, John E Sylvester, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2006
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphomaRichard I Fisher, Steven H Bernstein, Brad S Kahl, et al.
Clinical Trials (London, England)|October 23, 2009
Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting teamBrenda J Crowe, H Amy Xia, Jesse A Berlin, et al.
Cancer Discovery|October 3, 2019
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular CarcinomaMegan A Hatlen, Oleg Schmidt-Kittler, Cori Ann Sherwin, et al.
Blood|September 29, 2012
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasoneDavid I Lichter, Hadi Danaee, Michael D Pickard, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
American Journal of Hematology|January 6, 2015
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA studyMaría Victoria Mateos, Paul G Richardson, Meletios A Dimopoulos, et al.
ACS Applied Materials & Interfaces|May 25, 2019
Stability and Repeatability of a Karst-like Hierarchical Porous Silicon Oxide-Based MemristorQin Gao, Anping Huang, Qi Hu, et al.
ACS Omega|August 29, 2019
Broadband Emission in Hybrid Organic-Inorganic Halides of Group 12 MetalsRachel Roccanova, Matthew Houck, Aymen Yangui, et al.
Blood|March 17, 2012
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myelomaShaji Kumar, Ian Flinn, Paul G Richardson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2011
Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL studyNathan Fowler, Brad S Kahl, Peter Lee, et al.
European Urology|April 11, 2020
The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 TrialDavid P Dearnaley, Daniel R Saltzstein, John E Sylvester, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2006
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphomaRichard I Fisher, Steven H Bernstein, Brad S Kahl, et al.
Clinical Trials (London, England)|October 23, 2009
Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting teamBrenda J Crowe, H Amy Xia, Jesse A Berlin, et al.
Cancer Discovery|October 3, 2019
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular CarcinomaMegan A Hatlen, Oleg Schmidt-Kittler, Cori Ann Sherwin, et al.
Blood|September 29, 2012
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasoneDavid I Lichter, Hadi Danaee, Michael D Pickard, et al.
Pageof 8